Detail of "39262-14-1"

Reference

Fermented ginseng comprising deglycosylated ginsenosides and method for manufacturing the same to obtain health effective deglycosylated ginsenosides without generating side products, thereby being possible to eliminate separate purification process, and to improve sensory property by using Lactobacillus casei strain hasegawa for deglycosylation of ginsenosides

All Rights Reserved. Fermented ginseng comprising deglycosylated ginsenosides and method for manufacturing the same to obtain health effective deglycosylated ginsenosides without generating side products, thereby being possible to eliminate separate purification process, and to improve sensory property by using Lactobacillus casei strain hasegawa for deglycosylation of ginsenosides. Kim, Jae Baeg; Hasegawa, Hideo (S. Korea ). Repub. 39262-14-1 and 34080-08-5 are cas registry numbers. These chemicals are also mentioned in this article. Korean Kongkae Taeho Kongbo KR 2006074970 A 4 Jul 2006,No pp. given (Korean). (Korea, Republic Of). CODEN: KRXXA7. APPLICATION: KR 2004-113513 28 Dec 2004. DOCUMENT TYPE: Patent CA Section: 63 (Pharmaceuticals) Section cross-reference(s): 17 Fermented ginseng comprising deglycosylated ginsenosides and a method for manufg. the same are provided to obtain and to accumulate certain deglycosylated ginsenosides including 20S-protopanaxadiol 20-O-beta-D-glucopyranoside (FGM1) and 20S-protopanaxatriol (FGM4), which are known to have pharmacol. and physiol. functions related with immunity against tumors, to eliminate a purifying process after the fermn. process for obtaining the deglycosylated ginsenosides, and thus to improve the workability as well as the organoleptic quality of the resulted ginseng product. The fermented ginseng comprising deglycosylated ginsenosides is produced by: sterilizing the medium comprising a raw ginseng as a main ingredient; inoculating the medium with 0.1-20% Lactobacillus casei strain Hasegawa (FERMBP-10123:NIBH) based on the total wt. of the medium; and growing the culture under the conditions of 1-50% of concn. and 10-50 C and 25-37 C of a temp. for 12-40 days, wherein the resulted fermented ginseng can be directly used without purifn. .

Determination of a Ginseng Saponin Metabolite, IH901, in Rat Plasma by Liquid Chromatography-Tandem Mass Spectrometry

Determination of a Ginseng Saponin Metabolite, IH901, in Rat Plasma by Liquid Chromatography-Tandem Mass Spectrometry. Jeoung, Min Kyo; Chung, Youn Bok; Lee, Pung Sok; Kim, Chang Soo; Kim, Nam Hee; Son, Dong Ju; Hong, Jin Tae; Moon, Dong-Cheul ( College of Pharmacy, Chungbuk National University, Cheongju, Heungduk-Gu, S. Korea). Journal of Liquid Chromatography & Related Technologies, 28(20), 3205-3216 (English) 2005 Taylor & Francis, Inc. CODEN: JLCTFC. ISSN: 1082-6076. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) We developed a liq. chromatog.-tandem mass spectrometric (LC-MS/MS) method for the detn. of a ginseng saponin metabolite, IH901 or compd. K (20-O-b-D-glucopyranosyl-20(S)-protopanaxadiol) in rat plasma. The method involves protein pptn. by acetonitrile and HPLC sepn. of the sample exts. on a reversed-phase column (X-terra RP18) with isocratic elution of 20 mM ammonium acetate and acetonitrile (, vol./vol.), at a flow rate of 0.2 mL/min. The MS anal. was performed by electrospray pos. ionization mass spectrometry using multiple reaction-monitoring mode. The mass transitions of IH901 and prednisolone (internal std.) were m/z 640?425 and 361?343, resp. The std. curves for IH901 were linear over the concn. 39262-14-1 is also in the experiment. range of 2.0-500 ng/mL. The lower limit of quantification was 2 ng/mL and the limited of detection was 1 ng/mL for IH901. The coeff. of variation of intra- and inter-day assays at five quality control levels ranged from 2.0 to 13.9% and the accuracy varied between 93.2 and 110.5%. This method was used to det. IH901 in plasma samples after the oral administration of a single 30 mg/kg dose on SD rats. .